This clinical trial is focused on studying a type of blood cancer called Chronic Lymphocytic Leukemia (CLL). The study is comparing the effectiveness and safety of two different treatment combinations for patients who have not received treatment for CLL before and have other medical conditions. The first treatment combination includes Obinutuzumab and Venetoclax, while the second combination includes Obinutuzumab and Chlorambucil. Obinutuzumab is given as an infusion, which means it is delivered directly into the bloodstream through a vein, while Venetoclax and Chlorambucil are taken as tablets.
The purpose of the study is to determine which treatment combination is more effective in preventing the progression of CLL. Participants in the study will receive one of the two treatment combinations. The study will monitor the participants over a period to see how well the treatments work in controlling the disease and to observe any side effects. The study will also look at how long the treatments can keep the disease from getting worse and how they affect the overall health and survival of the participants.
Throughout the study, participants will have regular check-ups and tests to assess their health and the status of their CLL. These tests will help the researchers understand how the treatments are working and ensure the safety of the participants. The study aims to provide valuable information that could improve treatment options for people with CLL in the future.
Austria 
Bulgaria 
Croatia 
Denmark 
Estonia 
France 
Germany 
Italy 
Poland 
Romania 
Spain 